Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04973930
Other study ID # Velocity
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 1, 2022
Est. completion date December 31, 2024

Study information

Verified date February 2024
Source New York State Psychiatric Institute
Contact John C Markowitz, MD
Phone 646 774-8098
Email jcm42@cumc.columbia.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cancer and depression commonly occur together, and each worsens the other. We conducted a large psychotherapy study treating depression in breast cancer patients, showing that psychotherapy lowers symptoms. Surprisingly, no studies have compared depression-focused psychotherapy to antidepressant medication for patients with breast cancer and depression. We applied to the National Cancer Institute for a large, cross-national grant. Reviewers asked us to first demonstrate that patients would accept either psychotherapy or medication as treatment. Thanks to funding from the Columbia Herbert Irving Cancer Center, we will test this study approach. We will randomly assign 20 patients with both non-metastatic breast cancer and major depression to 12 weeks of tele-therapy (by Zoom) with either interpersonal psychotherapy or a serotonin reuptake inhibitor. We expect patients in both treatments to report improvement in depression symptoms. We will also measure C-reactive protein, a blood test of inflammation elevated in both cancer and depression, which may predict medication response.


Description:

Screening. All patients with non-metastatic, Stage I-III breast cancer who are undergoing care at HICCC will be offered the PHQ-9, a brief, reliable, widely used depression screener. This provides an opportunity to assess depression prevalence in the HICCC population. Patients who screen positive for likely major depression (PHQ-9 score ≥10; sensitivity 88%, specificity 88%)26 will be offered further evaluation and an explanation of the study. Independent evaluators trained to reliability will assess patient eligibility. Inclusion criteria: 1) Age ≥18 and <80; 2) diagnosis of diagnosis of Stage I-III breast cancer (<10 years from diagnosis), based on patient report and HICCC chart; 3) MDD episode without psychotic features on Structured Clinical Interview for DSM-5 (SCID-528); 4) 24-item Ham-D27 score ≥18; 5) written informed consent. Men and women are eligible. Exclusion criteria: 1) Psychosis (by SCID-5 interview); 2) current moderate/severe substance use disorder (mild substance disorder is not an exclusion) (by SCID-5); 3) acute suicidal risk (Ham-D suicide item score >2); 4) history of non-response to (>6 week) trials of venlafaxine (≥225 mg/d) and escitalopram (≥20 mg/d); 5) history of non-response to IPT (>4 sessions); 6) receiving current medication or psychotherapy treatment for depression; 7) acute medical instability (too physically debilitated to participate in trial) or delirium; 8) inability to complete self-administered questionnaires in English; 9) current enrollment in a therapeutic oncology trial; 10) known metastases. Eligible patients who consent will be randomly assigned in 1:1 ratio to 12 weeks of IPT or SRI (venlafaxine XR or escitalopram, based on treatment history). Study-eligible patients will be interviewed by a research assistant using an open-ended inventory of patient willingness and disinclination to participate in the study based on factors including treatment preference, tele-therapy preference, cell phone and computer broadband access, socioeconomic status and family burden, work conflicts, interpersonal support, and outside depression treatment. We will tabulate the number of patients already receiving antidepressant treatments, whose non-participation would not reflect on treatment acceptability or study participation. Treatments. As both treatments were initially intended to be delivered as tele-therapy in the multi-site SWOG grant proposal, they are well adapted to the Covid-19 era.9 All treatment sessions and all assessments (unless patient is visiting the HICCC in person and prefers this) will be conducted via HIPAA-secure Zoom. Tele-therapy has become standard treatment during the pandemic9 and may ease access for already burdened BC patients. Tele-therapy may improve current undertreatment of MDD among patients with BC. IPT is a well-defined, manualized, repeatedly proven treatment for depression.14,29 Dr. Markowitz, a leading IPT researcher with multiple NIH grant experience, including with tele-therapy,9,30 will supervise already trained IPT therapists based on recorded HIPAA-secure Zoom sessions. IPT defines depression as a treatable medical illness that is not the patient's fault, and which often arises in the context of distressing life events - such as the diagnosis of breast cancer, and the effect of cancer and its treatment on body image. In 12 50-minute weekly sessions, IPT helps patients understand and accept their feelings in an environmental context and to use their emotions to handle the crisis and build protective social support. Pharmacotherapy. Dr. Hellerstein, a clinical trials veteran, will provide expert supervision, supplementing a manualized medication approach.31 In our experience, venlafaxine (VLX) and escitalopram (ESC) are the two antidepressants best tolerated and least likely to interfere with oncotherapy for patients with MDD and breast cancer. Having minimal CYP2D6 inhibition and hence interfering less with tamoxifen and aromatase inhibitor metabolism, VLX makes sense as first choice; ESC mildly inhibits 2D6. Tele-sessions lasting 20-30 minutes will occur weekly for two weeks, then biweekly through week 12. Clinicians will raise doses as tolerated to ensure efficacy, assessing side effects by checklist, to a maximum of velafaxine XR 300 mg or escitalopram 30 mg daily. Pharmacotherapists will not conduct psychotherapy. Assessments will be conducted at baseline, midpoint, and end of treatment (weeks 0, 6, and 12) by raters reliably trained on instruments and blinded to treatment assignment. Self-reports will be conducted online using REDCap. Treatment sessions will be recorded for therapist adherence rating using the established CSPRS-6 scale.32 In addition to the rating instruments, the PI and co-PI will tele-interview all patients post-treatment to determine their level of and reasons for treatment satisfaction and dissatisfaction, and will debrief all study clinicians to determine their views of patient treatment acceptability, comfort, and satisfaction. The study will employ standard observer and self-report assessments. The PROMIS-2936 assesses not only psychiatric and medical symptom domains but quality of life and meaning and purpose, factors that might potentially distinguish treatment effects. We have previously used such scales to evaluate treatment trials, and similarly expect high levels in this study: clinician treatment fidelity (>95%), patient treatment preference, and patient satisfaction (>80% scores). We have allocated in the study budget $50 compensation for patients who complete their week 12 evaluations. Data analysis. 1. Descriptive statistics such as means with standard deviation, proportions, and counts will be reported to characterize BC patients that will be screened. 2. Point prevalence of depression at HICCC for patients with Stage I-III BC will be calculated. 3. Qualitative analysis will be used to report reasons eligible patients would participate in or decline the study. Zero-Inflated Poisson regression will be used to model both study participants and eligible BC patients who decline the study. 4. Paired t-test or Fisher's exact test will be used to compare outcome changes between baseline and end of study. Proportion responding (≥50% Ham-D-24 decrease from pre-treatment Ham-D-24) and remission rate (Ham-D-24 ≤7) will be the outcomes of interests.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - diagnosis of diagnosis of Stage I-III breast cancer (<10 years from diagnosis) - episode of major depressive disorder without psychotic features on Structured Clinical Interview for DSM-5 (SCID-5) - 24-item Hamilton Depression Rating Scale score =18 - written informed consent Exclusion Criteria: - Psychosis (by SCID-5 interview) - current moderate/severe substance use disorder (mild substance disorder is not an exclusion) - acute suicidal risk - history of non-response to (>6 week) trials of venlafaxine (=225 mg/d) and escitalopram (=20 mg/d); - history of non-response to IPT (>4 sessions - receiving current medication or psychotherapy treatment for depression - acute medical instability (too physically debilitated to participate in trial) or delirium - inability to complete self-administered questionnaires in English - current enrollment in a therapeutic oncology trial - known metastases

Study Design


Intervention

Behavioral:
Interpersonal Psychotherapy
Time-limited, affect-focused, empirically supported psychotherapy
Drug:
Venlafaxine HCl ER
FDA-approved antidepressant medications

Locations

Country Name City State
United States Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
New York State Psychiatric Institute Columbia University

Country where clinical trial is conducted

United States, 

References & Publications (4)

Blanco C, Markowitz JC, Hellerstein DJ, Nezu AM, Wall M, Olfson M, Chen Y, Levenson J, Onishi M, Varona C, Okuda M, Hershman DL. A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disord — View Citation

Blanco C, Markowitz JC, Hershman DL, Levenson JA, Wang S, Grann VR. A Pilot Study of Interpersonal Psychotherapy for Depressed Women with Breast Cancer. Am J Psychother. 2014;68(4):489-95. doi: 10.1176/appi.psychotherapy.2014.68.4.489. — View Citation

Markowitz JC, Hellerstein DJ, Falabella G, Lan M, Levenson J, Crew KD, Hershman DL. Psychopharmaphobia: Elevated fear of antidepressant medication among patients with major depression and breast cancer. Gen Hosp Psychiatry. 2023 Jul-Aug;83:117-122. doi: 1 — View Citation

Weissmann MM, Markowitz JC, Klerman GL: The Guide to Interpersonal Psychotherapy. New York, Oxford University Press, 2018. ISBN-13: 978-0190662592

Outcome

Type Measure Description Time frame Safety issue
Primary Hamilton Depression Rating Scale Observer-rated canonical measure of depression; 24-item version; higher scores= greater severity Change over twelve weeks
Secondary C-Reactive Protein Serum measure of inflammation; higher values= greater inflammation Change over twelve weeks
Secondary Posttraumatic Stress Checklist (PCL-5) Self-reported PTSD symptom questionnaire; higher scores= greater severity Change over twelve weeks
Secondary PROMIS PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health. We will use self-report measures of pain; physical and social functioning; associated symptoms; higher scores= greater severity Change over twelve weeks
Secondary Patient Health Questionnaire - 9 (PHQ-9) Brief 9-item self-report screen of depressive symptoms; higher scores= greater severity Change over twelve weeks
Secondary Perceived Social Support Scale-Self-Report Questionnaire measuring perceived social support; higher scores= greater support Change over twelve weeks
Secondary Social Adjustment Scale - Self-Report (SAS-SR) Established self-report scale measuring social functioning; higher scores= poorer functioning Change over twelve weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A